This article was originally published in The Gray Sheet
Executive SummaryGene-based cancer test firm is seeking additional funds for its North American operations via an equity financing, sale of non-strategic assets including its Research Products Division and interests in certain other affiliates, and "release of legal restrictions on the availability of certain cash deposits," the firm reports. Recently adopted cost-cutting measures include slicing its workforce by 40% in North America, which is anticipated to be completed by the end of the second quarter. A recent addition to an existing credit facility from a "major Oncor shareholder" brings available cash to approximately $3.2 mil. The Gaithersburg, Maryland firm is working with Lehman Brothers to "seek a major strategic transaction, including the possible sale of the company." The company disclosed in March plans to divest all non-oncology ventures in an effort to refocus the company ("The Gray Sheet" March 30, p. 26)
You may also be interested in...
Philips Expert Urges Device Makers: Update Quality Systems To Conform To Revised Risk Standard ISO 14971
It’s time for manufacturers to begin adopting the new 2019 version of ISO 14971, the international standard for risk management widely used by industry. But firms need to do more work than just changing the date on risk-related procedures and documents to “2019,” says Jos Van Vroonhoven, a senior manager at Philips Healthcare who was intimately involved with the standard’s redo. From conducting gap assessments to creating cross-functional teams, both Van Vroonhoven and longtime industry expert Don Powers tell Medtech Insight how firms can keep their quality systems up-to-date to conform to ISO 14971:2019.
Here’s a crosswalk for recently revised international risk management standard ISO 14971 and its 2007 predecessor.
Headed for its second reading in the Florida House after its counterpart passed the Senate on 29 January, HB 113 would expressly preempt local regulation of OTC drugs and cosmetics. According to House analysis documents, “This nullifies the current City of Key West ordinance” banning the sale of sunscreens containing reputed coral-killing UV filters.